A cohort study published in JAMA Network Open found that patients with breast cancer and pathogenic BRCA1/2 variants treated with breast-conserving therapy (BCT) had above-average risks of ipsilateral and contralateral breast cancer events, but most did not have another cancer event and rem...
1.第一项研究是一项meta分析,关于BRCA突变对乳腺癌预后影响的研究有很多,结果也不完全一致,我选择这项研究的原因有两个:第一个是这项研究的发表日期是2021年;第二个是研究发表在Breast cancer research and treatment这个杂志上,是乳腺癌领域的老牌杂志。 (Liu M, Xie F, Liu M, et al. Association between ...
we say that the critical word is optimization, treatment optimization. So trying to improve the way we care about our patients with breast cancer in terms of trying to reduce the burden of treatment when not so much treatm...
中国进展期乳腺癌共识指南共同组长和执笔人 Associate Editor of “Breast Cancer Research and Treatment” 56 ESMO 2024 · 目录 #ESMO 2024
Associate Editor of “Breast Cancer Research and Treatment” (来源:《肿瘤瞭望》编辑部) 声明 凡署名原创的文章版权属《肿瘤瞭望》所有,欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议,如果该信息被用于资讯以...
17. A.W. Kurian, P. Abrahamse, A.S. Hamilton, et al. Chemotherapy regimens received by women with BRCA1/2 pathogenic variants for early stage breast cancer treatment. JNCI Cancer Spectr, 6 (4) (2022), p. pkac045 CN-20240808-00006...
Associate Editor of “Breast Cancer Research and Treatment” 更多精彩内容, 请扫码订阅“ESMO 2024”专栏 (来源:《肿瘤瞭望》编辑部) 声明 凡署名原创的文章版权属《肿瘤瞭望》所有,欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导,...
Effective and Well-Tolerated Combo in ER+/HER2– Metastatic Breast Cancer Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER+ Breast Cancer Treatment T-DXd in ER+/HER2-Low Breast Cancer: Insights From DESTINY-Breast06 Expanding Access to Bispecifics in R/R Multiple Myeloma Treatment ...
1.FDA approves first treatment for breast cancer with a certain inherited genetic mutation. FDA News Release January 12, 2018 2. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine. June 4, 201...
Associate Editor of “Breast Cancer Research and Treatment” FABULOUS研究是一项评估氟唑帕利单药及联合阿帕替尼对比化疗治疗BRCA突变的HER2阴性乳腺癌的随机、对照Ⅲ期临床研究。该研究已达到主要终点,氟唑帕利+阿帕替尼或氟唑帕利单药治疗较标准化疗在BICR评估的PFS方面具有优越性。研究结果显示,与标准化疗相比,氟...